https://www.selleckchem.com/products/avelumab.html
021). Discontinuation due to adverse events was 35.3% and 12.2% in the standard and dose-escalation groups, respectively (P = 0.07. Median TTF was 10.4 months (95% confidential interval [CI] 2.6-31.3 months) and 18.0 months (95% CI 11.5-22.8 months) in the standard and dose-escalation groups, respectively (Hazard ratio 0.60, 95% CI 0.29-1.30, P = 0.194). With the ENZ dose-escalation strategy, adverse events related to ENZ of any grade and grade ≥3 were significantly decreased, and discontinuation due to adverse events also decreased.
Like
Comment
Share
